

NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 to 70 years old - no known IDH mutation - must consent and have tumor submitted within 30 days of surgery - adequate hematologic, kidney, and liver function (study staff will review)

Exclusion Criteria:

- previous treatment of the brain tumor - prior cancer (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years - women who are pregnant or breast feeding

Conditions & Interventions

Conditions:

Brain & Nervous System, Cancer

Keywords:

Brain Cancer, Brain Cancer, Glioblastoma

More Information

Description: We are looking at adding lomustine to temozolomide and radiation therapy when compared to temozolomide and radiation therapy alone (usual care). We will compare the effect (shrinking or stabilizing) and side effects when treating newly diagnosed MGMT methylated glioblastoma. Each of the drugs and radiation work in a different way to stop the growth of tumor cells.

Study Contact: Kristen Nelson - knelso65@fairview.org

Principal Investigator: Elizabeth Neil

IRB

Number: MMCORC043

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.